金活醫藥集團(01110.HK)業績快報:2019年純利升5.9%至4342.7萬元 末期息2.34港仙
格隆匯3月31日丨金活醫藥集團(01110.HK)公佈未經審核全年業績。2019年實現收益9.78億元人民幣(單位下同),同比下降9.4%;毛利2.67億元,同比下降14.2%,毛利率由上年同期的28.9%降至27.3%;公司擁有人應占溢利4342.7萬元,同比增長5.9%;每股基本盈利7分,擬派末期股息每股2.34港仙。
於回顧年度,集團於藥品分部的佔比為64.8%,佔約6.34億元,較去年同期輕微上升2.0%;保健品分部佔比為15.5%,佔約1.51億元,較去年同期下跌40.2%;醫療設備分部佔比為19.7%,佔約1.93億元,較去年同期下跌5.8%。
回顧年度,集團星級產品念慈庵產品系列繼續深化推進渠道優化工作,藉助念慈庵的品牌力和產品力,下沉縣域市場,增強終端覆蓋,強化與區域連鎖的強強合作,讓更多的消費者能夠體驗念慈庵的產品。
可是,2019年由於受市場宏觀經濟的影響,於回顧年度,京都念慈庵蜜煉川貝枇杷膏的收益較去年同期減少14.3%至約4.86億元;京都念慈庵枇杷糖的收益同比增加5.9%至約3900萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.